二甲双胍对于非癌性皮肤疾病的影响鲜有研究。本研究旨在调查与二甲双胍使用相关的免疫介导的皮肤疾病（如荨麻疹、过敏性接触性皮炎和银屑病）以及雄激素介导的皮肤疾病（如黑棘皮症、发汗腺炎和痤疮）。研究对象为在1999年至2009年期间处方抗糖尿病药物的二甲双胍使用者（n=234,585）和非二甲双胍使用者（n=125,921），并对其进行至2011年12月31日的随访观察。使用倾向性分数加权的Cox回归分析分别估计了意向治疗（ITT）和符合方案（PP）分析中二甲双胍使用者与非二甲双胍使用者的危险比。针对免疫介导的皮肤疾病，ITT和PP分析中的危险比分别为0.930（95%置信区间：0.920-0.940）和0.930（0.918-0.943），且每种具体结果的危险比均显著低于单位。针对雄激素介导的皮肤疾病，ITT和PP分析中的危险比分别为1.110（1.060-1.162）和0.990（0.935-1.048），除ITT分析中痤疮的危险比（1.116，95%置信区间：1.064-1.170）外，每种具体结果的危险比均不显著。总之，二甲双胍使用可以显著降低免疫介导的皮肤疾病的风险，但对于雄激素介导的皮肤疾病并没有预防效果。出版社：S. Karger AG, Basel。

Metformin's effects on non-cancer skin diseases are rarely investigated.To investigate immune-mediated (urticaria, allergic contact dermatitis and psoriasis) and androgen-mediated (acanthosis nigricans, hidradenitis suppurativa and acne) skin diseases associated with metformin use.Metformin initiators (n=234,585) and non-metformin initiators (n=125,921) within the initial 12 months of antidiabetic drugs prescription during 1999-2009 were followed up until December 31, 2011. Cox regression weighted for propensity score was used to estimate hazard ratios for metformin initiators versus non-metformin initiators in intention-to-treat (ITT) and per-protocol (PP) analyses.For immune-mediated skin diseases, hazard ratios were 0.930 (95% confidence interval: 0.920-0.940) and 0.930 (0.918-0.943) in ITT and PP analyses, respectively; and the hazard ratios for each specific outcome were all significantly below unity. For androgen-mediated skin diseases, the ITT and PP hazard ratios were 1.110 (1.060-1.162) and 0.990 (0.935-1.048), respectively; and all hazard ratios were not significant for each specific outcome except for acne in the ITT analysis (hazard ratio: 1.116, 95% confidence interval: 1.064-1.170).Metformin use is associated with a significantly lower risk of immune-mediated skin diseases but a lack of preventive effect on androgen-mediated skin diseases.S. Karger AG, Basel.